Beacon Therapeutics
- Biotech or pharma, therapeutic R&D
Beacon Therapeutics is a clinical-stage ocular gene therapy company founded to save and restore the vision of patients with a range of prevalent and rare blinding retinal diseases. The company’s pipeline includes clinical and preclinical programs to treat X-Linked Retinitis Pigmentosa (XLRP), dry Age-related Macular Degeneration (dAMD), and an inherited Cone Rod Dystrophy (CRD). Lead development candidate, laru-zova (AGTC-501), is currently in a pivotal Phase 2/3 trial of patients with XLRP, a severe, aggressive, inherited retinal disease that often leads to blindness by middle age, with no treatment options available.
Beacon is supported by funds from Syncona Limited, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences, and additional investors.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}